{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:32:56Z","timestamp":1784698376050,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1038\/nrendo.2010.125","type":"journal-article","created":{"date-parts":[[2010,8,19]],"date-time":"2010-08-19T11:06:53Z","timestamp":1282216013000},"page":"509-514","source":"Crossref","is-referenced-by-count":63,"title":["Phenylketonuria: a 21st century perspective"],"prefix":"10.1038","volume":"6","author":[{"given":"Francjan J.","family":"van Spronsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFnrendo2010125_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/humu.10192","volume":"21","author":"J Zschocke","year":"2003","unstructured":"Zschocke, J. Phenylketonuria mutations in Europe. Hum. Mutat. 21, 345\u2013356 (2003).","journal-title":"Hum. Mutat."},{"issue":"Suppl. 407","key":"BFnrendo2010125_CR2","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1111\/j.1651-2227.1994.tb13440.x","volume":"83","author":"I F\u00f8lling","year":"1994","unstructured":"F\u00f8lling I. The discovery of phenylketonuria. Acta Paediatr. 83 (Suppl. 407), S4\u2013S10 (1994).","journal-title":"Acta Paediatr."},{"key":"BFnrendo2010125_CR3","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/S0140-6736(53)90473-5","volume":"265","author":"H Bickel","year":"1953","unstructured":"Bickel, H., Gerrard, J. & Hickmans, E. M. Influence of phenylalanine intake on phenylketonuria. Lancet 265, 812\u2013813 (1953).","journal-title":"Lancet"},{"key":"BFnrendo2010125_CR4","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1542\/peds.32.3.338","volume":"32","author":"R Guthrie","year":"1963","unstructured":"Guthrie, R. & Susi, A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 32, 338\u2013343 (1963).","journal-title":"Pediatrics"},{"key":"BFnrendo2010125_CR5","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s10545-007-0644-5","volume":"30","author":"JG Loeber","year":"2007","unstructured":"Loeber, J. G. Neonatal screening in Europe; the situation in 2004. J. Inherit. Metab. Dis. 30, 430\u2013438 (2007).","journal-title":"J. Inherit. Metab. Dis."},{"issue":"Suppl. 1","key":"BFnrendo2010125_CR6","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1016\/j.ymgme.2005.09.011","volume":"86","author":"MR Zurfl\u00fch","year":"2005","unstructured":"Zurfl\u00fch, M. R. et al. Screening for tetrahydrobiopterin deficiencies using dried blood spots on filter paper. Mol. Genet. Metab. 86 (Suppl. 1), S96\u2013S103 (2005).","journal-title":"Mol. Genet. Metab."},{"issue":"Suppl. 1","key":"BFnrendo2010125_CR7","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1016\/j.ymgme.2009.10.008","volume":"99","author":"FJ van Spronsen","year":"2010","unstructured":"van Spronsen, F. J. & Enns, G. M. Future treatment strategies in phenylketonuria. Mol. Gen. Metab. 99 (Suppl. 1), S90\u2013S95 (2010).","journal-title":"Mol. Gen. Metab."},{"key":"BFnrendo2010125_CR8","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1136\/adc.65.5.472","volume":"65","author":"I Smith","year":"1990","unstructured":"Smith, I., Beasley, M. G. & Ades, A. E. Intelligence and quality of dietary treatment in phenylketonuria. Arch. Dis. Child. 65, 472\u2013478 (1990).","journal-title":"Arch. Dis. Child."},{"key":"BFnrendo2010125_CR9","first-page":"2533","volume":"134","author":"PH Verkerk","year":"1990","unstructured":"Verkerk, P. H., Vaandrager, G. J. & Sengers R. C. 15 years of national screening for phenylketonuria in The Netherlands; 4th Report of the National Commission for Management of Phenylketonuria [in Dutch]. Ned Tijdschr Geneeskd. 134, 2533\u20132536 (1990).","journal-title":"Ned Tijdschr Geneeskd."},{"key":"BFnrendo2010125_CR10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.pediatrneurol.2005.05.003","volume":"33","author":"R Gassi\u00f3","year":"2005","unstructured":"Gassi\u00f3, R. et al. School performance in early and continuously treated phenylketonuria. Pediatr. Neurol. 33, 267\u2013271 (2005).","journal-title":"Pediatr. Neurol."},{"key":"BFnrendo2010125_CR11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1037\/0894-4105.17.3.369","volume":"17","author":"SC Huijbregts","year":"2003","unstructured":"Huijbregts, S. C. et al. Motor function under lower and higher controlled processing demands in early and continuously treated phenylketonuria. Neuropsychology 17, 369\u2013379 (2003).","journal-title":"Neuropsychology"},{"issue":"Suppl. 1","key":"BFnrendo2010125_CR12","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.ymgme.2009.10.007","volume":"99","author":"S Christ","year":"2010","unstructured":"Christ, S. E, Huijbregts, S. C., de Sonneville, L. M. & White, D. A. Executive function in early-treated phenylketonuria: Profile and underlying mechanisms. Mol. Gen. Metab. 99 (Suppl. 1), S22\u2013S32 (2010).","journal-title":"Mol. Gen. Metab."},{"issue":"Suppl. 1","key":"BFnrendo2010125_CR13","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1016\/j.ymgme.2009.10.183","volume":"99","author":"JK Gentile","year":"2010","unstructured":"Gentile J. K., Ten Hoedt, A. E. & Bosch, A. M. Psychosocial aspects of PKU: hidden disabilities. Mol. Gen. Metab. 99 (Suppl. 1), S64\u2013S67 (2010).","journal-title":"Mol. Gen. Metab."},{"key":"BFnrendo2010125_CR14","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s10545-008-0918-6","volume":"31","author":"FJ van Spronsen","year":"2008","unstructured":"van Spronsen, F. J. & Burgard, P. The truth of treating patients with phenylketonuria after childhood: the need for a new guideline. J. Inherit. Metab. Dis. 31, 673\u2013679 (2008).","journal-title":"J. Inherit. Metab. Dis."},{"key":"BFnrendo2010125_CR15","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.neubiorev.2008.11.001","volume":"33","author":"J Albrecht","year":"2009","unstructured":"Albrecht, J., Garbade, S. F. & Burgard, P. Neuropsychological speed tests and blood phenylalanine levels in patients with phenylketonuria: a meta-analysis. Neurosci. Biobehav. Rev. 33, 414\u2013421 (2009).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"BFnrendo2010125_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1023\/A:1020158631102","volume":"25","author":"R Koch","year":"2002","unstructured":"Koch, R. et al. Phenylketonuria in adulthood: A collaborative study. J. Inherit. Metab. Dis. 25, 333\u2013346 (2002).","journal-title":"J. Inherit. Metab. Dis."},{"key":"BFnrendo2010125_CR17","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1542\/peds.99.3.345","volume":"99","author":"J Pietz","year":"1997","unstructured":"Pietz, J. et al. Psychiatric disorders in adult patients with early-treated phenylketonuria. Pediatrics 99, 345\u2013350 (1997).","journal-title":"Pediatrics"},{"issue":"Suppl. 1","key":"BFnrendo2010125_CR18","first-page":"14","volume":"30","author":"PJ Lee","year":"2007","unstructured":"Lee, P. J., McKitterick, K., Channon, S. & Leach, A. Improvements in neuropsychometric outcome when re-introducing diet in adulthood in phenylketonuria (PKU). J. Inherit. Metab. Dis. 30 (Suppl. 1), 14 (2007).","journal-title":"J. Inherit. Metab. Dis."},{"issue":"Suppl. 1","key":"BFnrendo2010125_CR19","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1016\/j.ymgme.2009.10.014","volume":"99","author":"R Koch","year":"2010","unstructured":"Koch, R., Trefz, F. & Waisbren, S. Psychosocial issues and outcomes in maternal PKU. Mol. Gen. Metab. 99 (Suppl. 1), S68\u2013S74 (2010).","journal-title":"Mol. Gen. Metab."},{"key":"BFnrendo2010125_CR20","doi-asserted-by":"publisher","first-page":"E199","DOI":"10.1111\/j.1750-3841.2009.01134.x","volume":"74","author":"CE Laclair","year":"2009","unstructured":"Laclair, C. E., Ney, D. M., MacLeod, E. L. & Etzel, M. R. Purification and use of glycomacropeptide for nutritional management of phenylketonuria. J. Food Sci. 74, E199\u2013E206 (2009).","journal-title":"J. Food Sci."},{"key":"BFnrendo2010125_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s10545-008-0952-4","volume":"32","author":"DM Ney","year":"2009","unstructured":"Ney, D. M. et al. Nutritional management of PKU with glycomacropeptide from cheese whey. J. Inherit. Metab. Dis. 32, 32\u201339 (2009).","journal-title":"J. Inherit. Metab. Dis."},{"key":"BFnrendo2010125_CR22","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ymgme.2007.06.004","volume":"92","author":"K Lim","year":"2007","unstructured":"Lim, K., van Calcar, S. C., Nelson, K. L., Gleason, S. T. & Ney, D. M. Acceptable low-phenylalanine foods and beverages can be made with glycomacropeptide from cheese whey for individuals with PKU. Mol. Genet. Metab. 92, 176\u2013178 (2007).","journal-title":"Mol. Genet. Metab."},{"key":"BFnrendo2010125_CR23","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.3945\/ajcn.2008.27280","volume":"89","author":"SC van Calcar","year":"2009","unstructured":"van Calcar, S. C. et al. Improved nutritional management of phenylketonuria by using a diet containing glycomacropeptide compared with amino acids. Am. J. Clin. Nutr. 89, 1068\u20131077 (2009).","journal-title":"Am. J. Clin. Nutr."},{"key":"BFnrendo2010125_CR24","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1001\/archneur.1976.00500100018008","volume":"33","author":"AE Andersen","year":"1976","unstructured":"Andersen, A. E. & Avins, L. Lowering brain phenylalanine levels by giving other large neutral amino acids. A new experimental therapeutic approach to phenylketonuria. Arch. Neurol. 33, 684\u2013686 (1976).","journal-title":"Arch. Neurol."},{"key":"BFnrendo2010125_CR25","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1172\/JCI5017","volume":"103","author":"J Pietz","year":"1999","unstructured":"Pietz, J. et al. Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J. Clin. Invest. 103, 1169\u20131178 (1999).","journal-title":"J. Clin. Invest."},{"key":"BFnrendo2010125_CR26","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1542\/peds.112.S4.1575","volume":"112","author":"RA Moats","year":"2003","unstructured":"Moats, R. A., Moseley, K. D., Koch, R. & Nelson, M. Jr. Brain phenylalanine concentrations in phenylketonuria: research and treatment of adults. Pediatrics 112, 1575\u20131579 (2003).","journal-title":"Pediatrics"},{"key":"BFnrendo2010125_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ymgme.2007.02.002","volume":"91","author":"S Schindeler","year":"2007","unstructured":"Schindeler, S. et al. The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study. Mol. Genet. Metab. 91, 48\u201354 (2007).","journal-title":"Mol. Genet. Metab."},{"key":"BFnrendo2010125_CR28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S0140-6736(85)90250-8","volume":"2","author":"H Lou","year":"1985","unstructured":"Lou, H. Large doses of tryptophan and tyrosine as potential therapeutic alternative to dietary phenylalanine restriction in phenylketonuria. Lancet 2, 150\u2013151 (1985).","journal-title":"Lancet"},{"key":"BFnrendo2010125_CR29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10545-007-0556-4","volume":"30","author":"R Matalon","year":"2007","unstructured":"Matalon, R. et al. Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine. J. Inherit. Metab. Dis. 30, 153\u2013158 (2007).","journal-title":"J. Inherit. Metab. Dis."},{"key":"BFnrendo2010125_CR30","first-page":"178","volume":"7","author":"S Kaufman","year":"1977","unstructured":"Kaufman, S. & Milstien, S. Phenylketonuria and its variants. Ann. Clin. Lab. Sci. 7, 178\u2013185 (1977).","journal-title":"Ann. Clin. Lab. Sci."},{"key":"BFnrendo2010125_CR31","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0022-3476(99)70138-1","volume":"135","author":"S Kure","year":"1999","unstructured":"Kure, S. et al. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J. Pediatr. 135, 375\u2013378 (1999).","journal-title":"J. Pediatr."},{"key":"BFnrendo2010125_CR32","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1007\/s10545-007-0605-z","volume":"30","author":"BK Burton","year":"2007","unstructured":"Burton, B. K. et al. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study. J. Inherit. Metab. Dis. 30, 700\u2013707 (2007).","journal-title":"J. Inherit. Metab. Dis."},{"key":"BFnrendo2010125_CR33","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1056\/NEJMoa021654","volume":"347","author":"AC Muntau","year":"2002","unstructured":"Muntau, A. C. et al. Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N. Engl. J. Med. 347, 2122\u20132132 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2010125_CR34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ymgme.2007.09.017","volume":"92","author":"H Levy","year":"2007","unstructured":"Levy, H., Burton, B., Cederbaum, S. & Scriver, C. Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH(4)) in phenylketonuria and its use in treatment. Mol. Genet. Metab. 92, 287\u2013291 (2007).","journal-title":"Mol. Genet. Metab."},{"key":"BFnrendo2010125_CR35","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S1096-7192(02)00171-3","volume":"77","author":"C Bernegger","year":"2002","unstructured":"Bernegger, C. & Blau, N. High frequency of tetrahydrobiopterin-responsiveness among hyperphenylalaninemias: a study of 1,919 patients observed from 1988 to 2002. Mol. Genet. Metab. 77, 304\u2013313 (2002).","journal-title":"Mol. Genet. Metab."},{"issue":"Suppl. 1","key":"BFnrendo2010125_CR36","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1016\/j.ymgme.2005.05.013","volume":"86","author":"JB Hennermann","year":"2005","unstructured":"Hennermann, J. B., B\u00fchrer, C., Blau, N., Vetter, B. & M\u00f6nch, E. Long-term treatment with tetrahydrobiopterin increases phenylalanine tolerance in children with severe phenotype of phenylketonuria. Mol. Genet. Metab. 86 (Suppl. 1), S86\u2013S90 (2005).","journal-title":"Mol. Genet. Metab."},{"key":"BFnrendo2010125_CR37","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/jhg.2009.37","volume":"54","author":"SF Dobrowolski","year":"2009","unstructured":"Dobrowolski, S. F. et al. A limited spectrum of phenylalanine hydroxylase mutations is observed in phenylketonuria patients in western Poland and implications for treatment with 6R tetrahydrobiopterin. J. Hum. Genet. 54, 335\u2013339 (2009).","journal-title":"J. Hum. Genet."},{"issue":"Suppl. 1","key":"BFnrendo2010125_CR38","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.ymgme.2005.06.009","volume":"86","author":"B P\u00e9rez","year":"2005","unstructured":"P\u00e9rez, B. et al. Kinetic and stability analysis of PKU mutations identified in BH4-responsive patients. Mol. Genet. Metab. 86 (Suppl. 1), S11\u2013S16 (2005).","journal-title":"Mol. Genet. Metab."},{"key":"BFnrendo2010125_CR39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ajhg.2008.05.013","volume":"83","author":"SW Gersting","year":"2008","unstructured":"Gersting, S. W. et al. Loss of function in phenylketonuria is caused by impaired molecular motions and conformational instability. Am. J. Hum. Genet. 83, 5\u201317 (2008).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrendo2010125_CR40","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ymgme.2009.01.002","volume":"96","author":"N Blau","year":"2009","unstructured":"Blau, N. et al. Optimizing the use of sapropterin (BH4) in the management of phenylketonuria. Mol. Genet. Metab. 96, 158\u2013163 (2009).","journal-title":"Mol. Genet. Metab."},{"key":"BFnrendo2010125_CR41","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1073\/pnas.96.5.2339","volume":"96","author":"CN Sarkissian","year":"1999","unstructured":"Sarkissian, C. N. et al. A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase. Proc. Natl Acad. Sci. USA 96, 2339\u20132344 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrendo2010125_CR42","doi-asserted-by":"publisher","first-page":"20894","DOI":"10.1073\/pnas.0808421105","volume":"105","author":"CN Sarkissian","year":"2008","unstructured":"Sarkissian, C. N. et al. Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria. Proc. Natl Acad. Sci. USA 105, 20894\u201320899 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrendo2010125_CR43","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ymgme.2009.09.002","volume":"99","author":"TS Kang","year":"2010","unstructured":"Kang, T. S. et al. Converting an injectable protein therapeutic into an oral form: phenylalanine ammonia lyase for phenylketonuria. Mol. Genet. Metab. 99, 4\u20139 (2010).","journal-title":"Mol. Genet. Metab."},{"key":"BFnrendo2010125_CR44","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/sj.gt.3302678","volume":"13","author":"CO Harding","year":"2006","unstructured":"Harding, C. O. et al. Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2\/8 vector-mediated gene therapy in murine phenylketonuria. Gene Ther. 13, 457\u2013462 (2006).","journal-title":"Gene Ther."},{"key":"BFnrendo2010125_CR45","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/sj.gt.3302684","volume":"13","author":"Z Ding","year":"2006","unstructured":"Ding, Z., Georgiev, P. & Th\u00f6ny, B. Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer. Gene Ther. 13, 587\u2013593 (2006).","journal-title":"Gene Ther."},{"key":"BFnrendo2010125_CR46","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/mt.2008.17","volume":"16","author":"Z Ding","year":"2008","unstructured":"Ding, Z. et al. Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system. Mol. Ther. 16, 673\u2013681 (2008).","journal-title":"Mol. Ther."},{"key":"BFnrendo2010125_CR47","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1089\/hum.2009.127","volume":"21","author":"A Rebuffat","year":"2010","unstructured":"Rebuffat, A., Harding, C. O., Ding, Z. & Th\u00f6ny, B. Comparison of adeno-associated virus pseudotype 1, 2, and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuria. Hum. Gene Ther. 21, 463\u2013477 (2010).","journal-title":"Hum. Gene Ther."},{"key":"BFnrendo2010125_CR48","doi-asserted-by":"crossref","unstructured":"Th\u00f6ny, B. Long-term correction of murine phenylketonuria by viral gene transfer: liver versus muscle. J. Inherit. Metab. Dis. doi:10.1007\/s10545-010-9044-3.","DOI":"10.1007\/s10545-010-9044-3"},{"key":"BFnrendo2010125_CR49","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev.genom.7.080505.115737","volume":"7","author":"N Gregersen","year":"2006","unstructured":"Gregersen, N., Bross, P., Vang, S. & Christensen, J. H. Protein misfolding and human disease. Annu. Rev. Genomics Hum. Genet. 7, 103\u2013124 (2006).","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"BFnrendo2010125_CR50","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/nature02265","volume":"426","author":"FE Cohen","year":"2003","unstructured":"Cohen, F. E. & Kelly, J. W. Therapeutic approaches to protein-misfolding diseases. Nature 426, 905\u2013909 (2003).","journal-title":"Nature"},{"key":"BFnrendo2010125_CR51","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1172\/JCI34355","volume":"118","author":"AL Pey","year":"2008","unstructured":"Pey, A. L. et al. Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria. J. Clin. Invest. 118, 2858\u20132867 (2008).","journal-title":"J. Clin. Invest."}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2010.125","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2010.125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2010.125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T22:38:22Z","timestamp":1685745502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrendo.2010.125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["BFnrendo2010125"],"URL":"https:\/\/doi.org\/10.1038\/nrendo.2010.125","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}